8-K: Zai Lab Announces Q1 2025 Financial Results: Revenue Up 22%, Profitability on Track

Zai Lab reports a 22% year-over-year revenue increase to $106.5 million in Q1 2025 and reaffirms its full-year revenue guidance of $560 million to $590 million.

Summary

• Zai Lab Limited announced its financial results for the first quarter of 2025.
• Total revenues grew 22% year-over-year to $106.5 million.
• The company reaffirmed its full-year 2025 revenue guidance of $560 million to $590 million.
• Operating loss improved significantly, declining 20% year-over-year to $56.3 million, and 25% on an adjusted basis to $37.1 million.
• Zai Lab is on track to achieve profitability in the fourth quarter of 2025.
• ZL-1310 (DLL3 ADC) is advancing rapidly, with upcoming ASCO 2025 data presentation and initiation of a registrational study expected in the second half of 2025.
• The company's cash position is strong, with $857.3 million as of March 31, 2025.
• Product revenue, net was $105.7 million in the first quarter of 2025, compared to $87.1 million for the same period in 2024, representing 21% y-o-y growth, 23% y-o-y growth at constant exchange rate (CER).
• Net loss was $48.4 million in the first quarter of 2025, or a loss per ordinary share attributable to common stockholders of $0.04 (or loss per American Deposit Share (ADS) of $0.45), compared to a net loss of $53.5 million for the same period in 2024, or a loss per ordinary share of $0.05 (or loss per ADS of $0.55).

Sentiment

Score: 7

Explanation: The sentiment is positive due to revenue growth, improved operating loss, and a clear path to profitability. However, the net loss and seasonal slowdown of VYVGART temper the overall optimism.

Positives

• Revenue increased by 22% year-over-year to $106.5 million.
• Operating loss improved by 20% year-over-year.
• Adjusted operating loss improved by 25% year-over-year.
• The company is on track to achieve profitability in Q4 2025.
• Strong cash position of $857.3 million as of March 31, 2025.
• VYVGART sales increased due to market coverage and NRDL listing.
• ZEJULA sales remained strong as the leading PARP inhibitor in China.
• NUZYRA sales increased due to market coverage and penetration.

Negatives

• The company experienced a net loss of $48.4 million in Q1 2025.
• VYVGART sales experienced a seasonal slowdown early in the year.
• Cash and cash equivalents decreased from $879.7 million as of December 31, 2024, to $857.3 million as of March 31, 2025.

Risks

• The company's ability to successfully commercialize and generate revenue from approved products.
• The company's ability to obtain funding for its operations and business initiatives.
• The results of clinical and pre-clinical development of product candidates.
• Decisions made by regulatory authorities regarding approvals of product candidates.
• Risks related to doing business in China.

Future Outlook

Zai Lab anticipates a return to strong sequential growth throughout the rest of the year, fueled by late-stage pipeline products like bemarituzumab and KarXT, alongside VYVGART. The company is on track to achieve profitability in the fourth quarter of 2025.

Management Comments

• In the first quarter, we continued to advance both our global pipeline and commercial business, said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab.
• We are rapidly expanding our global portfolio, having recently presented promising data for two next-generation oncology therapies at AACR, and we look forward to presenting updated results for ZL-1310 (DLL3 ADC) at the 2025 ASCO Annual Meeting.
• We remain on track to initiate a pivotal study for ZL-1310 in SCLC this year, with the goal of securing FDA approval in 2027.
• 2025 marks a transformational year for Zai Lab, and we are executing against the key objectives we set at the start of the year, said Josh Smiley, President and COO of Zai Lab.
• Following a seasonal slowdown of VYVGART early in the year, we saw patient volumes rebound in March and April, and we anticipate a return to strong sequential growth throughout the rest of the year.
• At the same time, we continue to strengthen our financial position, achieving a 20% year-over-year reduction in operating loss and a 25% year-over-year reduction in adjusted operating loss, keeping us on track to achieve profitability in the fourth quarter of 2025.

Industry Context

Zai Lab's focus on oncology, immunology, neuroscience, and infectious diseases aligns with current trends in the biopharmaceutical industry. The company's strategic collaborations and pipeline development efforts position it to compete with other global biopharmaceutical companies in these therapeutic areas.

Comparison to Industry Standards

• Zai Lab's revenue growth of 22% year-over-year is comparable to other commercial-stage biopharmaceutical companies in the Asia-Pacific region.
• The company's focus on innovative therapies and strategic partnerships mirrors the approach of companies like BeiGene and Innovent Biologics.
• Zai Lab's pipeline development in oncology and immunology is consistent with the industry's focus on these high-growth therapeutic areas.
• The company's goal of achieving profitability in Q4 2025 is a key milestone that will be closely watched by investors and analysts.

Stakeholder Impact

• Shareholders can expect potential long-term value creation due to revenue growth and pipeline advancement.
• Employees may benefit from the company's expansion and strategic initiatives.
• Patients may gain access to innovative therapies for oncology, immunology, neuroscience, and infectious diseases.
• Suppliers and partners can expect continued collaboration and business opportunities.
• Creditors can be reassured by the company's strong cash position and path to profitability.

Next Steps

• Present updated data for ZL-1310 (DLL3 ADC) at the 2025 ASCO Annual Meeting on June 2, 2025.
• Initiate a pivotal study for ZL-1310 in SCLC in the second half of 2025.
• Provide a data readout for dose escalation of ZL-1310 doublet in combination with atezolizumab.
• Advance ZL-1503 (IL-13/IL-31R) into a global Phase 1 study in atopic dermatitis.
• Advance ZL-6201 (LRRC15 ADC) into global Phase 1 development for patients with sarcoma and other LRRC15-positive solid tumors.
• Amgen to provide data readout from the Phase 3 FORTITUDE-101 study of bemarituzumab in first-line gastric cancer in the second quarter of 2025.
• Amgen to provide data readout from the Phase 3 FORTITUDE-102 study of bemarituzumab in first-line gastric cancer in the second half of 2025.
• Bristol Myers Squibb (BMS) to provide data readout from the Phase 3 ADEPT-2 study of KarXT in Alzheimer's Disease Psychosis in the second half of 2025.
• Argenx to provide topline results from the Phase 3 ADAPT-SERON study in seronegative gMG.
• Provide topline results from the Phase 2 study in Lupus Nephritis (LN).
• Partner with Vertex to execute the global pivotal Phase 2/3 study of povetacicept in pMN in Greater China.

Key Dates

Keywords

Zai Lab, Financial Results, Q1 2025, Revenue, Profitability, Oncology, Immunology, Pharmaceuticals, Clinical Trials, ZL-1310, VYVGART, ZEJULA, NUZYRA